Cleo Diagnostics Ltd
COV
Company Profile
Business description
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company’s first product to market is intended to be the Triage Test which results to accurately differentiate patients with malignant ovarian cancer from those with benign gynecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.
Contact
480 Collins Street
Level 2
MelbourneVIC3000
AUST: +61 396140600
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Avoid this overvalued ASX lithium producer
Why the market may be overpricing future earnings for this lithium producer.
stocks
Morningstar's verdict on SpaceX
Mark and Shani run through the business and what our analysts think about the IPO.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,994.70 | 7.20 | -0.08% |
| CAC 40 | 8,340.71 | 59.40 | -0.71% |
| DAX 40 | 24,893.58 | 246.11 | -0.98% |
| Dow JONES (US) | 51,666.84 | 45.87 | -0.09% |
| FTSE 100 | 10,428.85 | 9.00 | -0.09% |
| HKSE | 23,344.67 | 8.39 | 0.04% |
| NASDAQ | 25,587.04 | 579.56 | -2.21% |
| Nikkei 225 | 68,980.21 | 808.17 | -1.16% |
| NZX 50 Index | 13,382.87 | 52.90 | -0.39% |
| S&P 500 | 7,365.46 | 107.33 | -1.44% |
| S&P/ASX 200 | 8,793.00 | 8.40 | -0.10% |
| SSE Composite Index | 4,096.14 | 10.11 | -0.25% |